Plus Therapeutics (NASDAQ:PSTV) Receives "Buy" Rating from D. Boral Capital

Key Points

• Plus Therapeutics has received a "buy" rating from D. Boral Capital with a target price of $5.00, amidst mixed ratings from other analysts.
• The company's stock price recently opened at $0.58, with a market cap of $57.50 million and a 12-month high of $2.31.
• Insider transactions show significant activity, as Director Robert P. Lenk bought 110,000 shares, increasing their ownership by 375.08%.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock.

Several other research analysts have also recently issued reports on the stock. Maxim Group lowered their target price on shares of Plus Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Monday, August 18th. Zacks Research upgraded shares of Plus Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of Plus Therapeutics from $5.50 to $3.00 and set a "buy" rating for the company in a research report on Friday, June 27th. Finally, Ascendiant Capital Markets upped their price target on shares of Plus Therapeutics from $20.50 to $21.00 and gave the company a "buy" rating in a research report on Monday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $8.00.

Plus Therapeutics Trading Down 6.6%

Shares of Plus Therapeutics stock opened at $0.58 on Tuesday. The company has a fifty day simple moving average of $0.56 and a 200-day simple moving average of $0.52. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.31. The stock has a market cap of $57.50 million, a price-to-earnings ratio of -0.26 and a beta of 0.81.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.08. The company had revenue of $1.39 million during the quarter, compared to analyst estimates of $1.08 million. On average, analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Robert P. Lenk acquired 110,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was bought at an average price of $0.49 per share, for a total transaction of $53,900.00. Following the transaction, the director owned 139,327 shares in the company, valued at $68,270.23. This represents a 375.08% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.79% of the company's stock.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,030 shares of the company's stock, valued at approximately $38,000. Virtu Financial LLC owned about 0.24% of Plus Therapeutics as of its most recent filing with the SEC. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.